Dendritic cell vaccines for cancer immunotherapy

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 507-529

  Timmerman, John M ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Cytotoxic T lymphocyte; T cell; Tumor immunology

Indexed keywords

ANTIGEN; CANCER VACCINE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CLINICAL TRIALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, NON-HODGKIN; MELANOMA; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PILOT PROJECTS; REMISSION INDUCTION; T-LYMPHOCYTES; VACCINES;

EID: 0033051081     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.507     Document Type: Review

References (111)

1. 1. Schreiber H. 1993. Tumor immunology. In Fundamental Immunology, ed. WE Paul, pp. 1143-77. New York: Raven. 3rd ed.
2. 2. Roth C, Rochlitz C, Kourilsky P. 1994. Immune response against tumors. Adv. Immunol. 57:281-351
3. 3. Kawakami Y, Robbins PF, Storkus WJ, Lotze MT. 1995. Biology of tumor antigens. In Biologic Therapy of Cancer, ed. VT DeVita, S Hellman, SA Rosenberg, pp. 53-77. Philadelphia: Lippincott. 2nd ed.
4. 4. Rosenberg SA. 1997. Principles of cancer management:biologic therapy. In Cancer: Principles and Practice of Oncology, ed. VT Devita, S Hellman, SA Rosenberg, pp. 349-73. Philadelphia: Lippincott-Raven. 5th ed.
5. 5. Pardoll DM. 1993. Cancer vaccines. Immunol. Today 14:310-16
6. 6. Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. 1997. Antigens recognized by T-lymphocytes on human tumours. Biochem. Soc. Trans. 25:544-48
7. 7. Tjoa B, Boynton A, Kenny G, et al. 1996. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28: 65-69
8. 8. Boon T, Cerottini JC, Van den Eynde B, et al. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-65
9. 9. Kwak LW, Campbell MJ, Czerwinski DK, et al. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209-15
10. 10. Robbins PF, Kawakami Y. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628-36
11. 11. Tsang KY, Zaremba S, Nieroda CA, et al. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87:982-90
12. 12. Correale P, Walmsley K, Nieroda C, et al. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293-300
13. 13. Valone F, Small E, Peshwa MV, et al. 1998. Phase 1 trial of dendritic cell-based immunotherapy with APC8015 for hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Cancer Res. 39:173 (Abstr.)
14. 14. Houghton AN. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4
15. 15. Pardoll DM. 1998. Cancer vaccines. Nat. Med. 4:525-31
16. 16. Steinman RM, Cohn ZA. 1973. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137:1142-62
17. 17. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-96
18. 18. Ricciardi-Castagnoli P, ed. 1997. Dendritic Cells in Fundamental and Clinical Immunology, Volume 3. Vol. 417. Advances in Experimental Medicine and Biology. New York: Plenum
19. 19. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-52
20. 20. Hart DN. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-87
21. 21. Bennett SR, Carbone FR, Karamalis F, et al. 1997. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186:65-70
22. 22. Guinan EC, Gribben JG, Boussiotis VA, et al. 1994. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261-82
23. 23. Zhou LJ, Tedder TF. 1995. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin super-family. J. Immunol. 154:3821-35
24. 24. Shortman K, Caux C. 1997. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 15:409-19
25. 25. Inaba K, Inaba M, Naito M, Steinman RM. 1993. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178:479-88
26. 26. Sallusto F, Cella M, Danieli C, Lanzavecchia A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389-400
27. 27. Steinman RM, Swanson J. 1995. The endocytic activity of dendritic cells. J. Exp. Med. 182:283-88
28. 28. Jiang W, Swiggard WJ, Heufler C, et al. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151-55
29. 29. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-18
30. 30. Albert ML, Sauter B, Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
31. 31. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, et al. 1997. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387:713-17
32. 32. Koch F, Stanzl U, Jennewein P, et al. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741-46
33. 33. Dubois B, Vanbervliet B, Fayette J, et al. 1997. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J. Exp. Med. 185:941-51
34. 34. Lu L, McCaslin D, Starzl TE, Thomson AW. 1995. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 60:1539-45
35. 35. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493-97
36. 36. Gabrilovich DI, Nadaf S, Corak J, et al. 1996. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol. 170: 111-19
37. 37. Gabrilovich DI, Ciernik IF, Carbone DP. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:101-10
38. 38. Gabrilovich DI, Chen HL, Girgis KR, et al. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-103
39. 39. Steinbrink K, Wolfl M, Jonuleit H, et al. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-80
40. 40. Qin Z, Noffz G, Mohaupt M, Blankenstein T. 1997. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:770-76
41. 41. Mehta-Damani A, Markowicz S, Engleman EG. 1995. Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur. J. Immunol. 25:1206-11
42. 42. Young JW, Steinman RM. 1990. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J. Exp. Med. 171: 1315-32
43. 43. Mehta-Damani A, Markowicz S, Engleman EG. 1994. Generation of antigen-specific CD8+ CTLs from naive precursors. J. Immunol 153:996-1003
44. 44. Ridge JP, Di Rosa F, Matzinger P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-78
45. 45. Bhardwaj N, Bender A, Gonzalez N, et al. 1994. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J. Clin. Invest. 94:797-807
46. 46. Inaba K, Metlay JP, Crowley MT, Steinman RM. 1990. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172:631-40
47. 47. Takahashi H, Nakagawa Y, Yokomuro K, Berzofsky JA. 1993. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849-57
48. 48. Porgador A, Gilboa E. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255-60
49. 49. Shimizu J, Suda T, Yoshioka T, et al. 1989. Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells. J. Immunol. 142:1053-59
50. 50. Grabbe S, Bruvers S, Gallo RL, et al. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146: 3656-61
51. 51. Flamand V, Sornasse T, Thielemans K, et al. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24: 605-10
52. 52. Ossevoort MA, Feltkamp MC, van Veen KJ, et al. 1995. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis Tumor Immunol. 18:86-94
53. 53. Inaba K, Inaba M, Romani N, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702
54. 54. Mayordomo JI, Zorina T, Storkus WJ, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302
55. 55. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-87
56. 56. Porgador A, Snyder D, Gilboa E. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918-26
57. 57. Paglia P, Chíodoni C, Rodolfo M, Colombo MP. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-22
58. 58. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med 183:87-97
59. 59. Mayordomo JI, Loftus DJ, Sakamoto H, et al. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med 183: 1357-65
60. 60. Arthur JF, Butterfield LH, Roth MD, et al. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17-25
61. 61. Boczkowski D, Nair SK, Snyder D, Gilboa E. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med 184: 465-72
62. 62. Brossart P, Goldrath AW, Butz EA, et al. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158: 3270-76
63. 63. Song W, Kong HL, Carpenter H, et al. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-56
64. 64. Specht JM, Wang G, Do MT, et al. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186: 1213-21
65. 65. Gong J, Chen D, Kashiwaba M, Kufe D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558-61
66. 66. Gong J, Chen D, Kashiwaba M, et al. 1998. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95:6279-83
67. 67. Freudenthal PS, Steinman RM. 1990. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc. Natl. Acad Sci. USA 87:7698-702
68. 68. Markowicz S, Engleman EG. 1990. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 85:955-61
69. 69. Romani N, Gruner S, Brang D, et al. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93
70. 70. Zhou LJ, Tedder TF. 1996. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. USA 93:2588-92
71. 71. Morse MA, Zhou LJ, Tedder TF, et al. 1997. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann. Surg. 226: 6-16
72. 72. Romani N, Reider D, Heuer M, et al. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196: 137-51
73. 73. Bender A, Sapp M, Schuler G, et al. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196:121-35
74. 74. Reddy A, Sapp M, Feldman M, et al. 1997. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90:3640-46
75. 75. Siena S, Di Nicola M, Bregni M, et al. 1995. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp. Hematol. 23:1463-71
76. 76. Bernhard H, Disis ML, Heimfeld S, et al. 1995. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1099-104
77. 77. Brossart P, Stuhler G, Flad T, et al. 1998. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732-36
78. 78. Bakker AB, Marland G, de Boer AJ, et al. 1995. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res. 55: 5330-34
79. 79. Nair SK, Boczkowski D, Morse M, et al. 1998. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16:364-69
80. 80. Reeves ME, Royal RE, Lam JS, et al. 1996. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672-77
81. 81. Tuting T, Wilson CC, Martin DM, et al. 1998. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J. Immunol. 160:1139-47
82. 82. Mortarini R, Anichini A, Di Nicola M, et al. 1997. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res. 57: 5534-41
83. 83. Hsu FJ, Engleman EG, Levy R, et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58
84. 84. Miller RA, Maloney DG, Warnke R, Levy R. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306:517-22
85. 85. Timmerman JM, Levy R. 1997. Linkage of foreign carrier protein or GM-CSF to a tumor antigen improves the efficacy of pulsed dendritic cell vaccination. Blood 90:514a
86. 86. Reichardt VL, Okada CY, Stockerl-Goldstein KE, et al. 1997. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol. Blood Marrow Transplant. 3:157-63
87. 87. Bohlen H, Diehl V, Tesch H, et al. 1997. Dendritic cell-based idiotype vaccination in multiple myeloma. Blood 90:579a
88. 88. Wen YJ, Ling M, Bailey-Wood R, Lim SH. 1998. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 4:957-62
89. 89. Rosenberg SA. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175-82
90. 90. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-27
91. 91. Marchand M, Weynants P, Rankin E, et al. 1995. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63:883-85
92. 92. Jäeger E, Bernhard H, Romero P, et al. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162-69
93. 93. Hu X, Chakraborty NG, Sporn JR, et al. 1996. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56:2479-83
94. 94. Mukherji B, Chakraborty NG, Yamasaki S, et al. 1995. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA 92:8078-82
95. 95. Nestle FO, Alijagic S, Gilliet M, et al. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-32
96. 96. Lotze MT, Hellerstedt B, Stolinski L, et al. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3:S109
97. 97. Salgallar M, Lodge PA, Tjoa BA, et al. 1998. Monitoring of prostate-specific membrane antigen (PSMA)-specific immune responses and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides. Proc. Am. Assoc. Cancer Res. 39:173 (Abstr.)
98. 98. Murphy G, Tjoa B, Ragde H, et al. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371-80
99. 99. Schuler G, Steinman RM. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186: 1183-87
100. 100. Lebsack ME, McKenna HJ, Hoek R, et al. 1997. Safety of FLT3 ligand in healthy volunteers. Blood 90:170a
101. 101. Dietz AB, Vuk-Pavlovic S. 1998. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91:392-98
102. 102. Kim DT, Mitchell DJ, Brockstedt DG, et al. 1997. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159:1666-68
103. 103. Fong L, Ruegg CL, Brockstedt D, et al. 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159:3113-17
104. 104. Celluzi CM, Louis D, Falo J. 1998. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160:3081-85
105. 105. Pardoll DM. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399-415
106. 106. Tao MH, Levy R. 1993. Idiotype/ granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755-58
107. 107. Apostolopoulos V, Pietersz GA, Loveland BE, et al. 1995. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92:10128-32
108. 108. Condon C, Watkins SC, Celluzzi CM, et al. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122-28
109. 109. Maraskovsky E, Brasel K, Teepe M, et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-62
110. 110. Lynch DH, Andreasen A, Maraskovsky E, et al. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625-31
111. 111. Yee C, Riddell SR, Greenberg PD. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702-8